首页> 外文期刊>International Journal of Pharmaceutical Sciences and Research >NEGLIGIBLE EFFECT OF SOME COUNTERFEIT ANTI-OBESITY DRUGS
【24h】

NEGLIGIBLE EFFECT OF SOME COUNTERFEIT ANTI-OBESITY DRUGS

机译:一些假冒抗肥胖药物的效果可忽略不计

获取原文
       

摘要

Objective: To evaluate the effect of some counterfeit anti-obesity drugs that are not licensed by the Ministry of Health. Materials and Methods: 100 male rats were divided into 10 groups. The first group received a normal diet for two months. The second group received a high-fat diet (HFD) for two months; the third group received HFD for one month then returned to a normal diet. The remaining seven groups received HFD for one month then treated with Orlistat, Turbo slim (dose 1), Turbo slim (dose 2), African mango (dose1), African mango (dose 2), Slim factor (dose 1), and Slim factor (dose 2) respectively for an additional one month. Bodyweight, glucose, insulin, leptin, adiponectin, MCP-1, reduced glutathione, MDA, lipid profile, kidney, and liver functions were measured. Adipose tissue index, atherosclerosis index, HOMA-IR, and QUICKI were calculated. Results: Feeding with HFD induced a significant increase in body weight as well as insulin resistance, serum lipids, serum leptin, plasma MCP-1, and tissue MDA and a significant decrease in serum adiponectin and tissue GSH as compared to the normal group. These measurements were significantly reversed after cessation of HFD. Treatment with orlistat significantly reduced serum TAG, insulin resistance, serum leptin, and plasma MCP-1 and significantly increased serum adiponectin and tissue GSH as compared to group ceased HFD. There is no notable changes observed in groups treated with the other three drugs as compared to group ceased HFD. Conclusion: Our data show that the three studied counterfeit drugs had a negligible anti-obesity effect in comparison with registered Orlistat.
机译:目的:评价卫生部不许可的伪造抗肥胖药物的效果。材料和方法:将100只雄性大鼠分成10组。第一个组接受了正常饮食两个月。第二组接受了2个月的高脂饮食(HFD);第三组收到HFD一个月,然后恢复正常饮食。剩下的七组收到HFD一个月,然后用Orlistat,Turbo Slim(剂量1),涡轮增长(剂量2),非洲芒果(Dose1),非洲芒果(剂量2),超薄因子(剂量1)和纤细因子(剂量2)分别额外一个月。测量体重,葡萄糖,胰岛素,瘦素,脂联素,MCP-1,降低的谷胱甘肽,MDA,脂质谱,肾脏和肝功能。计算脂肪组织指数,动脉粥样硬化指数,HOMA-IR和Quicki。结果:与正常组相比,患有HFD的喂养体重和胰岛素抗性,血清脂质,血清瘦素,血浆MCP-1和组织MDA显着降低,以及血清脂联素和组织GSH的显着降低。在停止HFD后,这些测量显着逆转。与基团停止HFD相比,用Orlistat治疗血清标签,胰岛素抗性,血清瘦素和血浆MCP-1和显着增加的血清脂联素和组织GSH。与A组停止的HFD相比,在另外三种药物治疗的组中没有观察到的变化。结论:我们的数据显示,与注册Orlistat相比,这三种研究的假冒药物具有可忽略不计的抗肥胖效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号